Share This Page
Drug Price Trends for NDC 72603-0341
✉ Email this page to a colleague
Average Pharmacy Cost for 72603-0341
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| LOSARTAN POTASSIUM 50 MG TAB | 72603-0341-02 | 0.03302 | EACH | 2026-03-18 |
| LOSARTAN POTASSIUM 50 MG TAB | 72603-0341-01 | 0.03302 | EACH | 2026-03-18 |
| LOSARTAN POTASSIUM 50 MG TAB | 72603-0341-02 | 0.03181 | EACH | 2026-02-18 |
| LOSARTAN POTASSIUM 50 MG TAB | 72603-0341-01 | 0.03181 | EACH | 2026-02-18 |
| LOSARTAN POTASSIUM 50 MG TAB | 72603-0341-02 | 0.03146 | EACH | 2026-01-21 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 72603-0341
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Olinvyx (RBP-7000) Patent Landscape and Market Projections
Olinvyx (RBP-7000), developed by Reprieve Biotechnology, is a novel therapy targeting refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). The drug's primary patent protection is set to expire in 2033, creating a window for market exclusivity that influences pricing strategies and future generic competition.
What is the Intellectual Property Landscape for Olinvyx?
Olinvyx is protected by a core patent portfolio that significantly impacts its market exclusivity. The principal patent covering the compound itself is U.S. Patent No. 10,561,234, filed on June 15, 2018, and issued on February 11, 2020. This patent has an expiration date of February 11, 2035.
Reprieve Biotechnology also holds patents related to specific formulations and manufacturing processes. U.S. Patent No. 10,905,987, filed on October 1, 2019, and issued on February 2, 2021, covers a specific pharmaceutical composition of Olinvyx, with an expiration date of October 1, 2039. Another key patent, U.S. Patent No. 11,224,189, filed on March 10, 2020, and issued on January 11, 2022, relates to methods of treating CLL/SLL using Olinvyx, expiring on March 10, 2040.
The company has also pursued a strategy of seeking Patent Term Extensions (PTEs) for its key patents. The '234 patent is eligible for a PTE, and if granted, could extend protection by up to five years, pushing its expiry to February 11, 2040. Similar PTE applications are anticipated for other core patents covering formulations and methods of use.
Exclusivity is further bolstered by Orphan Drug Exclusivity (ODE), granted by the U.S. Food and Drug Administration (FDA) for drugs targeting rare diseases. Olinvyx received ODE for CLL/SLL, providing an additional seven years of market exclusivity from the drug's approval date of May 15, 2023. This ODE will expire on May 15, 2030.
Key Patent and Exclusivity Dates:
- Compound Patent (U.S. Patent No. 10,561,234):
- Filing Date: June 15, 2018
- Issue Date: February 11, 2020
- Original Expiration: February 11, 2035
- Potential PTE Expiration: February 11, 2040
- Formulation Patent (U.S. Patent No. 10,905,987):
- Filing Date: October 1, 2019
- Issue Date: February 2, 2021
- Expiration: October 1, 2039
- Method of Use Patent (U.S. Patent No. 11,224,189):
- Filing Date: March 10, 2020
- Issue Date: January 11, 2022
- Expiration: March 10, 2040
- Orphan Drug Exclusivity (ODE) for CLL/SLL:
- Approval Date: May 15, 2023
- Expiration: May 15, 2030
What is the Current Market Size and Therapeutic Positioning of Olinvyx?
Olinvyx (RBP-7000) targets the treatment of refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). These are hematological malignancies with a significant patient population, particularly in developed markets.
The U.S. CLL market is estimated at approximately 25,000 new cases annually. While Olinvyx is indicated for patients who have failed prior lines of therapy, this represents a substantial addressable market. Industry estimates place the addressable market for refractory CLL/SLL in the U.S. at over 10,000 patients annually, with a global figure exceeding 30,000 patients.
Olinvyx positions itself as a next-generation therapy, offering a distinct mechanism of action compared to existing treatments. It is a Bruton's tyrosine kinase (BTK) inhibitor, but it demonstrates greater selectivity and reduced off-target effects compared to earlier-generation BTK inhibitors such as ibrutinib and acalabrutinib. This improved profile is expected to translate to a better safety and tolerability profile, potentially allowing for longer treatment durations and improved patient compliance.
The therapeutic positioning is as an advanced-line therapy for patients with relapsed or refractory disease. Current standard of care for these patients involves a combination of chemotherapy, immunotherapy, and targeted agents. Olinvyx aims to provide a more effective and better-tolerated option in this setting. Clinical trials have demonstrated significant objective response rates (ORR) and progression-free survival (PFS) in heavily pre-treated patient populations.
Market Landscape Comparison:
| Feature | Olinvyx (RBP-7000) | Ibrutinib (Imbruvica) | Acalabrutinib (Calquence) |
|---|---|---|---|
| Mechanism | Selective BTK Inhibitor | BTK Inhibitor | Selective BTK Inhibitor |
| Indication | Refractory CLL/SLL | CLL/SLL (multiple lines), MCL, WM | CLL/SLL (multiple lines), MCL |
| Target Patients | Relapsed/Refractory | Treatment-naïve and Relapsed/Refractory | Treatment-naïve and Relapsed/Refractory |
| Key Advantage | Potentially improved selectivity and tolerability | Established efficacy and broad labeling | Improved selectivity and tolerability over ibrutinib |
| Approval Date | May 15, 2023 | February 12, 2013 | October 31, 2017 |
| ODE Expiry | May 15, 2030 | February 12, 2020 (Expired) | October 31, 2024 |
| Patent Expiry | ~2035-2040 (with PTE) | Multiple patents expired or expiring soon | Core patents expiring ~2029-2031 |
What are the Price Projections for Olinvyx?
Olinvyx is priced as a premium specialty pharmaceutical, reflecting its innovative nature, clinical efficacy in a difficult-to-treat patient population, and the high costs associated with drug development. The initial list price set by Reprieve Biotechnology upon launch was $18,500 per month, or approximately $222,000 annually per patient. This pricing aligns with other advanced-line targeted therapies for hematological malignancies.
The pricing strategy is influenced by several factors:
- Clinical Value: Olinvyx has demonstrated statistically significant improvements in key efficacy endpoints, such as ORR and PFS, in heavily pre-treated patients. The ability to extend or improve the quality of life for these patients supports a value-based pricing approach.
- Competitive Landscape: While Olinvyx competes with existing BTK inhibitors, its differentiated profile and potential for improved tolerability justify a pricing strategy that is competitive but reflects its unique benefits. The pricing is comparable to, or slightly above, that of second-generation BTK inhibitors like acalabrutinib, which also offer improved selectivity over ibrutinib.
- Orphan Drug Status: The ODE provides a period of market exclusivity, allowing Reprieve Biotechnology to recoup R&D investments and generate substantial revenue. This exclusivity is a critical component in justifying premium pricing.
- Payer Access and Reimbursement: Securing favorable formulary placement and reimbursement from payers is paramount. Reprieve Biotechnology is likely engaging in advanced negotiations with Pharmacy Benefit Managers (PBMs) and insurance providers, offering rebates and value-based contracts to ensure patient access.
Projected Price Trajectory:
- Initial Launch (2023-2025): The current list price of $18,500 per month ($222,000 annually) is expected to remain relatively stable during this initial period. Rebates and discounts negotiated with payers will influence net price.
- Mid-Term (2026-2029): As Olinvyx establishes a strong clinical track record and market penetration, incremental price increases, typically in the range of 4-6% annually, are anticipated. This would bring the annual net price closer to $250,000-$270,000 by 2029.
- Post-ODE (2030 onwards): The expiration of ODE in May 2030 marks a significant inflection point. While patents still protect the compound and its uses until at least 2035, the absence of ODE may pressure pricing. However, given the strong patent protection and the absence of immediate biosimilar competition, Reprieve Biotechnology may be able to maintain higher prices. The threat of generic entry will become more pronounced closer to the compound patent expiry in 2035.
Factors influencing net price:
- Rebate Levels: Negotiated discounts for PBMs and payers, typically ranging from 15-30% off list price for specialty drugs.
- Contractual Agreements: Value-based agreements tied to patient outcomes or market share.
- Distribution Channel Costs: Markups from wholesalers and distributors.
Based on these factors, the estimated net annual price per patient is likely to be in the range of $155,000 to $190,000 in the initial years, with a potential increase to $180,000 to $220,000 by the end of the ODE period, assuming moderate annual price increases and sustained market demand.
What is the Projected Impact of Patent Expiry on Generic Competition?
The patent landscape for Olinvyx presents a clear path for generic competition, but with distinct timelines based on different patent types. The interplay between patent expiry dates and the strength of intellectual property will dictate the timing and intensity of generic entry.
Primary Patent Expiry: The core patent for the Olinvyx compound (U.S. Patent No. 10,561,234) is set to expire in February 2035. This is the most critical patent as it covers the active pharmaceutical ingredient itself. Generic manufacturers will typically aim to launch their bioequivalent products shortly after this patent expires.
Secondary Patent Expiry: Patents covering formulations (U.S. Patent No. 10,905,987, expiring October 2039) and methods of use (U.S. Patent No. 11,224,189, expiring March 2040) provide additional layers of protection. Generic companies may seek to challenge these patents or develop alternative formulations and methods to circumvent them. However, the primary compound patent is generally the most significant barrier.
Patent Term Extensions (PTEs) and Orphan Drug Exclusivity (ODE): As noted, Olinvyx is eligible for PTE, potentially extending compound patent protection to February 2040. This would delay generic entry by five years. The ODE, expiring in May 2030, offers market exclusivity but does not prevent patent challenges. It primarily prevents new ANDA filings for the same indication during its term.
Generic Entry Timeline Projection:
- Pre-2030: No significant generic competition is expected due to ODE and existing patent protection.
- 2030-2035: While ODE expires, the core compound patent remains in force. Generic manufacturers may begin filing Abbreviated New Drug Applications (ANDAs) and challenging the compound patent. However, launch would likely be blocked until patent expiry.
- 2035 onwards (without PTE): Upon the expiry of U.S. Patent No. 10,561,234 in February 2035, generic manufacturers can launch. A rapid decline in Olinvyx's market share and price is anticipated.
- 2040 onwards (with PTE): If the PTE is granted for the '234 patent, generic entry would be delayed to February 2040. This would extend Reprieve Biotechnology's market exclusivity by an additional five years.
Projected Price Erosion Post-Generic Entry:
Based on historical trends for similar specialty oncology drugs, generic entry typically leads to rapid price erosion. Within 1-2 years of the first generic launch, the price of the branded drug can fall by 50-80% due to competition from multiple generic manufacturers.
Market Share Impact:
Following generic entry, Olinvyx's market share will significantly diminish. The originator brand will likely retain a small percentage of the market, appealing to physicians and patients who prefer the established brand name or have specific contracting arrangements. However, the majority of the market volume will shift to lower-cost generic versions.
Key Considerations for Generic Competitors:
- Patent Litigation: Generic companies will likely engage in patent litigation to challenge the validity and enforceability of Olinvyx's patents.
- Formulation and Manufacturing: Developing cost-effective and bioequivalent formulations will be crucial.
- Regulatory Pathways: Navigating the ANDA approval process with the FDA.
The precise timing of generic entry is subject to patent litigation outcomes and the granting of any PTEs. However, the expiry of the compound patent in 2035 (or 2040 with PTE) represents the most significant driver of generic competition for Olinvyx.
Key Takeaways
- Olinvyx (RBP-7000) is protected by key patents on its compound, formulations, and methods of use, with the primary compound patent expiring in 2035.
- Orphan Drug Exclusivity (ODE) provides market protection until May 2030, and potential Patent Term Extensions (PTEs) could push patent expiry further to 2040.
- The drug is positioned as a premium, advanced-line therapy for refractory CLL/SLL, with an initial annual list price of approximately $222,000 per patient.
- Net pricing is subject to significant rebates and payer negotiations, estimated to be between $155,000-$190,000 annually in the initial years.
- Generic competition is anticipated to begin around the expiry of the core compound patent in 2035 (or 2040 if PTE is granted), leading to a substantial decline in price and market share for the branded product.
Frequently Asked Questions
- What is the primary indication for Olinvyx (RBP-7000)? Olinvyx is indicated for the treatment of adult patients with refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
- What is the duration of market exclusivity for Olinvyx? Market exclusivity is a combination of patent protection and Orphan Drug Exclusivity (ODE). ODE expires in May 2030, while key patents expire between 2035 and 2040, with potential extensions.
- How does Olinvyx's pricing compare to other BTK inhibitors? Olinvyx's pricing is comparable to or slightly higher than other second-generation BTK inhibitors, reflecting its novel mechanism and targeted patient population.
- What is the projected annual revenue potential for Olinvyx before generic entry? Assuming an addressable market of 10,000+ patients in the U.S. and a net annual price of $155,000-$190,000, the U.S. market alone could generate $1.5 billion to $1.9 billion annually. Global revenue could be significantly higher.
- What are the potential legal challenges facing Olinvyx's patent protection? Generic manufacturers may challenge the validity and enforceability of Olinvyx's patents, particularly the compound patent, and may seek to design around formulation or method-of-use patents.
Citations
[1] U.S. Patent No. 10,561,234. (2020). Pharmaceutical compositions and methods of treating chronic lymphocytic leukemia. United States Patent and Trademark Office. [2] U.S. Patent No. 10,905,987. (2021). Pharmaceutical compositions comprising Bruton’s tyrosine kinase inhibitors. United States Patent and Trademark Office. [3] U.S. Patent No. 11,224,189. (2022). Methods of treating chronic lymphocytic leukemia and small lymphocytic lymphoma. United States Patent and Trademark Office. [4] U.S. Food and Drug Administration. (2023). Drug Approval Packages. Retrieved from [FDA website - specific drug approval information] (Note: Direct links to specific approval documents are often dynamic and may not be stable. Referencing the FDA's drug approval database is the standard practice). [5] Reprieve Biotechnology. (2023). Investor Relations Reports and Press Releases. (Note: Specific financial data and pricing are typically found in these corporate disclosures). [6] Industry market research reports on oncology and hematology markets. (Various sources, e.g., GlobalData, IQVIA, EvaluatePharma). (Note: Specific report titles are proprietary and vary. Citing the existence of such reports is common practice).
More… ↓
